The Latest

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is on the upswing. Track the latest deals here.

    Japan’s Asahi Kasei Corp. has agreed to acquire Calliditas Therapeutics for about $1.1 billion, adding to what’s already been a busy dealmaking season.

    Updated 15 hours ago
  • Two young scientists using a digital tablet
    Image attribution tooltip
    Marco VDM via Getty Images
    Image attribution tooltip
    Sponsored by Cognizant

    The future of medicine: AI’s role in uncovering new drugs

    Artificial intelligence (AI) has sparked a revolution in the pharmaceutical industry, reshaping the way we approach complex biological challenges.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Roche’s Sabry retires; Duchenne drug fails confirmatory test

    The veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative Phase 3 data and Merck unveiled new breast cancer results for Keytruda.

  • A U.S. flag flying above a building showing a sign with the word Lilly written in red.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly to pour $5B more into expanding Zepbound, Mounjaro production

    The planned spending on new facilities in Lebanon, Indiana, brings its total commitment to the site to $9 billion, the largest single manufactuing investment in company history.

  • Physicians, researchers and healthcare professionals attend ASCO's annual Meeting on June 2, 2023 in Chicago.
    Image attribution tooltip

    ASCO / Nick Agro

    Image attribution tooltip
    ASCO24

    Certain menopausal hormone therapy could raise ovarian cancer risk, study finds

    The findings, from two trials involving thousands of women, could influence guidelines around use of hormonal treatment for menopause symptoms.

  • The Nasdaq Marketplace is seen on March 01, 2024 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Cytokinetics secures up to $575M in royalty deal, frustrating investors

    The biotech’s decision to give Royalty Pharma a greater share of future drug sales suggests a lower likelihood it is readying to be acquired, analysts said.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Cancer drug developer Actuate Therapeutics is the third biotech to IPO plans in May. No startups have priced an offering since early April, however.

    Updated 14 hours ago
  • A 3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    Orna, a circular RNA specialist, acquires a buzzy startup

    After laying off staff late last year, Orna is expanding through the purchase of ReNAgade Therapeutics, which was built around technology designed to more effectively deliver RNA-based medicines.

  • Two people in laboratory gowns inspect biotechnology equipment with lettering spelling Millipore.
    Image attribution tooltip
    Courtesy of Millipore Sigma via Business Wire
    Image attribution tooltip

    Merck KGaA to buy gene therapy tools maker for $600M

    The German drugmaker is bolstering its MilliporeSigma business with a unit of Gamma Biosciences that specializes in so-called transfection reagents.

  • A chromatic Pfizer sign hangs on a building façade
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work?

    Direct-to-consumer platforms can offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.

  • Biogen
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen, looking to diversify, acquires immune drugmaker HI-Bio for $1.15B

    The deal, only Biogen’s third since the start of 2018, is a sign the company is open to branching out beyond the neurological drugs that have long been its focus. 

  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire here.

    Intellectual property is the foundation of the drug industry’s business model. This database will track key patent expiry dates for 30 top-selling medicines.

    Updated May 13, 2024
  • A portrait of Philip Larsen, CEO of SixPeaks Bio AG.
    Image attribution tooltip
    Permission granted by SixPeaks Bio AG
    Image attribution tooltip
    Obesity drugs

    SixPeaks, a new obesity biotech, starts up with an option to sell to AstraZeneca

    AstraZeneca has an exclusive chance to buy the startup, which is developing a muscle-protecting weight loss medicine, within the next two years.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Regeneron faces new biosimilar threats; an AI biotech lays off staff

    Today’s rundown also includes news of an expanded partnership for Boehringer Ingelheim and updates to emerging medicines from GSK and Bristol Myers. 

  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca’s $80B sales plan leans on cancer drug expansion

    The drugmaker aims to catch up in developing new tumor-fighting technologies — areas where it has lagged behind leaders like Novartis and J&J.

  • A person works in a laboratory at AltruBio.
    Image attribution tooltip
    Permission granted by AltruBio
    Image attribution tooltip
    Emerging biotech

    AltruBio lands up to $225M after shift to immune drug research

    Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.

  • Image attribution tooltip
    AstraZeneca
    Image attribution tooltip

    AstraZeneca sets sights on $80B in revenue by 2030

    The U.K. pharma expects to launch 20 new drugs by then, among them complex medicines for cancer as well as treatments for weight loss.

  • A headshot of Cyrus Mozayeni, CEO of Pheon Therapeutics.
    Image attribution tooltip
    Permission granted by Pheon Therapeutics
    Image attribution tooltip
    Emerging biotech

    Pheon rides wave of ADC interest with $120M financing

    CEO Cyrus Mozayeni said the company is taking a different approach than other developers of antibody-drug conjugates, though it’s keeping details close.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly partners with Aktis, deepening radiopharma investment

    The collaboration, which gives Lilly access to Aktis’ technology in return for $60 million, adds to a flurry of dealmaking in the radiopharma field.

  • A stock photo of blocks arranged to illustrate layoffs
    Image attribution tooltip
    Andrii Yalanskyi via Getty Images
    Image attribution tooltip

    BIO to restructure, lay off staff in shakeup of lobbying group

    Thirty employees will leave as part of the reorganization, which the group said is meant to bring "stronger focus and greater impact" to its work.

  • An illustration of a neuron cell network on a black background.
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Forbion-backed biotech Progentos debuts with $65M for MS drug

    Progentos says the money will go toward expanding its pipeline and pushing an experimental treatment for multiple sclerosis through "proof of concept” testing.

  • Image attribution tooltip
    Carl Court via Getty Images
    Image attribution tooltip

    European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug

    Rather than endorse the recommendation of the EMA, the commission called for a new review for Translarna that considers “the totality of the evidence” compiled to date.

  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Dyne shares jump on trial data for muscle disease drugs

    Updated study results for the biotech’s medicines for myotonic dystrophy Type 1 and Duchenne muscular dystrophy appeared to impress analysts and investors on Wall Street.

  • Large letters spelling Amgen are seen by a wall
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    FDA approves Amgen drug for tough-to-treat form of lung cancer

    Imdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following chemotherapy in treating extensive-stage small cell lung cancer.

    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Erasca restructures; Novartis moves to complete MorphoSys deal

    The cancer biotech is laying off one-fifth of its staff and scrapping three drugs. Elsewhere, Novartis secured sufficient support for its $3 billion buyout and Bristol Myers won a new CAR-T approval.

  • Weight loss GLP-1
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Obesity drugs

    Investors put $400M into biotech licensing obesity drugs from China

    The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.